Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 31 Genitourinary 9 Thoracic 8 Head & Neck 4 Gynecologic 4 CNS 4 Tumor-Agnostic 3 Gastrointestinal 2 Other solid neoplasm 1 Endocrine 1

Conditions

Thyroid Carcinoma, Anaplastic 1

Interventions

Everolimus 27 pembrolizumab 25 Temozolomide 24 lutetium Lu 177 dotatate 22 Nivolumab 18 Magnetic Resonance Spectroscopy 18 lenvatinib 17 cabozantinib 17 Cisplatin 16 Sunitinib 15 Capecitabine 14 Bevacizumab 14 Specimen Handling 12 Sorafenib 12 trametinib 10 Ipilimumab 10 Etoposide 10 pasireotide 9 dabrafenib 9 Paclitaxel 9 Carboplatin 8 pazopanib 7 lanreotide 7 Octreotide 7 Fluorodeoxyglucose F18 7 anlotinib 6 Irinotecan 6 Injections 6 Doxorubicin 6 surufatinib 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × sacituzumab govitecan × Endocrine × Clear all

NCT06235216 2024-11-01

SETHY

Grupo Espanol de Tumores Neuroendocrinos

Phase 2 Recruiting

EndocrineHead & Neck

Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡